- Home
- SG vs GLPG Comparison
SG vs GLPG Comparison
Compare SG & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SG
- GLPG
- Stock Information
- Founded
- SG 2007
- GLPG 1999
- Country
- SG United States
- GLPG Belgium
- Employees
- SG N/A
- GLPG N/A
- Industry
- SG Restaurants
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- SG Consumer Discretionary
- GLPG Health Care
- Exchange
- SG Nasdaq
- GLPG Nasdaq
- Market Cap
- SG 1.8B
- GLPG 2.1B
- IPO Year
- SG 2021
- GLPG 2005
- Fundamental
- Price
- SG $8.87
- GLPG $32.02
- Analyst Decision
- SG Buy
- GLPG Sell
- Analyst Count
- SG 15
- GLPG 4
- Target Price
- SG $18.36
- GLPG $25.33
- AVG Volume (30 Days)
- SG 5.6M
- GLPG 186.1K
- Earning Date
- SG 11-06-2025
- GLPG 10-29-2025
- Dividend Yield
- SG N/A
- GLPG N/A
- EPS Growth
- SG N/A
- GLPG N/A
- EPS
- SG N/A
- GLPG N/A
- Revenue
- SG $686,222,000.00
- GLPG $323,674,692.00
- Revenue This Year
- SG $8.56
- GLPG N/A
- Revenue Next Year
- SG $18.75
- GLPG N/A
- P/E Ratio
- SG N/A
- GLPG N/A
- Revenue Growth
- SG 5.74
- GLPG 5.43
- 52 Week Low
- SG $8.11
- GLPG $22.36
- 52 Week High
- SG $45.12
- GLPG $33.86
- Technical
- Relative Strength Index (RSI)
- SG 41.84
- GLPG 49.38
- Support Level
- SG $8.38
- GLPG $31.49
- Resistance Level
- SG $9.05
- GLPG $33.63
- Average True Range (ATR)
- SG 0.39
- GLPG 0.67
- MACD
- SG 0.14
- GLPG -0.07
- Stochastic Oscillator
- SG 56.77
- GLPG 41.45
About SG Sweetgreen Inc.
Sweetgreen Inc is a mission-driven, next-generation restaurant and lifestyle brand that serves healthy food at scale. Its bold vision is to be as ubiquitous as traditional fast food, but with the transparency and quality that consumers increasingly expect. It is creating plant-forward, seasonal, and earth-friendly meals from fresh ingredients and produce that prioritizes organic, regenerative, and local sourcing.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.